Antitumor effect of FP3 on a patient-derived tumor tissue xenograft model of rectal carcinoma.

Background/aims: FP3 is an engineered protein which contains the extracellular domain 2 of VEGF receptor 1 (Flt-1) and extracellular domain 3 and 4 of VEGF receptor 2 (Flk-1, KDR) fused to the Fc portion of human immunoglobulin G1. Previous studies demonstrated its antiangiogenic and antitumor effects in vitro and in vivo.

Methodology: In this study, a PDTT xenograft model of rectal carcinoma was established for assessment of the antitumor activity of FP3.